Posted on

mitchell’s medicinals cbd review

Yes, Mitchell’s Medicinals is devoted to sourcing the highest-quality natural ingredients for our products. Our hemp-derived CBD is non-GMO, ethanol extracted, and free of solvents.

Mitchell’s Medicinals’ 400 mg CBD topical ointment is a soothing salve for nerve and muscle relief.

Mitchell’s Medicinals 1000 mg (30 ml) concentrated CBD sublingual drops are ideal for sleep support, mood enhancement, anti-inflammatory relief and more.

Also important id Dr. Mechoulam’s discovery of the 2 cannabinoid receptors, CB1 and CB2. CB1 interacts with the central and peripheral nervous system. CB2 is responsible for the immune system.

Do you test your products for potency?

*All products contain less than 0.3% THC.

Concentrated CBD sublingual drops (1000mg bottle) are ideal for sleep support, mood enhancement, anti-inflammatory relief and more.

CBD has a broad range of therapeutic benefits, many of which are currently being studied in clinical trials. CBD serves as an anti-inflammatory and antioxidant, offering a natural pain relief option and a possible treatment for many conditions. CBD can also be incorporated into your daily health regimen for natural wellness.

What is hemp-derived CBD?

Research has shown that CBD has adaptogen qualities, meaning it works with receptors in the brain to modulate functions of the nervous system to achieve homeostasis. Put simply, it finds what is not working right and acts to fix it.

We proudly offer the highest quality CBD products in the Industry! Mitchell’s Medicinals hemp-derived CBD extracts are full spectrum, non-psychotropic, non-GMO, ethanol extracted, free of solvents, and legal in all 50 states!

It’s only been a few weeks since I started using the CBG OIL. I noticed a difference in my hands in the first couple of days. Definitely would recommend this product to my friends.

It’s only been a few weeks since I…

Dear Sir to whom it may concern.
I have tried to apply for my veterans discount only to find the web link you provided is not valid.
Could you please help in this matter.
I have place my order and hope to get my 15% discount applied to my order.
My order number is #4427, Dec 06/2019
Thank you
The item I use is good.
John Stone

Dear Sir to whom it may concern.

Reply from Mitchells Medicinals

Mitchell's medicinals cbd review

An open-label observational study of 22 patients with Parkinson’s disease attending a motor disorder clinic at a tertiary medical center collected data before and 30 minutes after patients smoked 0.5 grams of cannabis (Lotan et al., 2014). The instruments utilized included the UPDRS, the McGill Pain Scale, and a survey of subjective efficacy and adverse effects of cannabis. In addition, the effect of cannabis on motor symptoms was evaluated by two raters. The investigators found that the total motor symptoms score on the UPDRS improved from 33.1 (± 13.8) to 23.2 (± 10.5) (p <0.001). Subcategories of the UPDRS that showed statistically significant improvement included tremor, rigidity, and bradykinesia. Pain and sleep were also reported to be improved after smoking cannabis. The results from this low-quality observational study prompted the investigators to propose that their findings should be confirmed in a larger, longer, randomized, double-blind, placebo-controlled trial.

In Chapter 12, the committee reviews epidemiological evidence to examine the association between cannabis use and the development of schizophrenia and other psychoses, as well as the impact of cannabis use on the disorder’s course or symptoms.

The committee did not identify any good-quality primary literature that reported on medical cannabis as an effective treatment to reduce depressive symptoms and that were published subsequent to the data collection period of the most recently published good- or fair-quality systematic review addressing the research question.

Are Cannabis or Cannabinoids an Effective Treatment for Dystonia?

Primary Literature Pharmacological interventions in the treatment of anorexia nervosa have not been promising to date. Andries et al. (2014) conducted a prospective, randomized, double-blind, controlled crossover trial in 24 women with anorexia nervosa of at least 5 years’ duration attending both psychiatric and somatic therapy as inpatients or outpatients. In addition to their standard psychotherapy and nutritional interventions, the participants received dronabinol 2.5 mg twice daily for 4 weeks and a matching placebo for 4 weeks, randomly assigned to two treatment sequences (dronabinol/placebo or placebo/dronabinol). The primary outcome was weight change assessed weekly. The secondary outcome was change in Eating Disorder Inventory-2 (EDI-2) scores. The participants had a significant weight gain of 1.00 kg (95% CI = 0.40–1.62) during dronabinol therapy and 0.34 kg (95% CI = −0.14–0.82) during the placebo (p = 0.03). No statistically different differences in EDI-2 score changes were seen during treatment with dronabinol or the placebo, suggesting that there was no real effect on the participants’ attitudinal and behavioral traits related to eating disorders. The authors acknowledged the small sample size and the short duration of exposure, as well as the potential psychogenic effects, but they concluded that low-dose dronabinol is a safe adjuvant palliative therapy in a highly selected subgroup of chronically undernourished women with anorexia nervosa.

Tourette syndrome is a neurological disorder characterized by sporadic movements or vocalizations commonly called “tics” (NINDS, 2014). While there is currently no cure for Tourette syndrome, recent efforts have explored whether cannabis may be effective in reducing symptoms commonly associated with the disorder (Koppel et al., 2014).

Primary Literature

Huntington’s disease is characterized by chorea (abnormal, involuntary movement) along with cognitive decline and psychiatric impairment (Armstrong and Miyasaki, 2012). Worsening chorea significantly impacts patient quality of life. The pathophysiology and neurochemical basis of Huntington’s disease are incompletely understood. Neuroprotective trials often investigate agents that may decrease oxidative stress or glutamatergic changes related to excitotoxic stress. There is some preclinical evidence and limited clinical evidence that suggest that changes in the endocannabinoid system may be linked to the pathophysiology of Huntington’s disease (Pazos et al., 2008; van Laere et al., 2010).

Only 1 trial (n = 50) that examined inhaled cannabis was included in the effect size estimates from Whiting et al. (2015). This study (Abrams et al., 2007) also indicated that cannabis reduced pain versus a placebo (OR, 3.43, 95% CI = 1.03–11.48). It is worth noting that the effect size for inhaled cannabis is consistent with a separate recent review of 5 trials of the effect of inhaled cannabis on neuropathic pain (Andreae et al., 2015). The pooled ORs from these trials contributed to the Bayesian pooled effect estimate of 3.22 for pain relief versus placebo (95% CI = 1.59–7.24) tested across 9 THC concentrations. There was also some evidence of a dose-dependent effect in these studies.